

September 27, 2017

To members of the press:

Nichi-Iko Pharmaceutical Co., Ltd.
(Code No. 4541, TSE First Section)
ZERIA Pharmaceutical Co., Ltd.
(Code No. 4559, TSE First Section)

About Joint Promotion of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko"

We hereby announce that Nichi-Iko Pharmaceutical Co., Ltd. (Head office: Toyama-shi, Toyama Prefecture; President & CEO: Yuichi Tamura, hereinafter, Nichi-Iko) and ZERIA Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Tokyo; President & COO: Mitsuhiro Ibe, hereinafter, ZERIA Pharmaceutical), will jointly promote the biosimilar drug Infliximab BS for I.V. Infusion 100mg "Nichi-Iko," for which Nichi-Iko received manufacturing and marketing approval today.

Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" is a biosimilar generic of Infliximab, which is used in the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Today, Nichi-Iko received manufacturing and marketing approval for the drug.

Nichi-Iko is confident that joint promotions with ZERIA Pharmaceutical, which has expertise in the field of digestive organs, will maximize the value of this product.

With the launch of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko," we will provide new therapy options to patients with autoimmune inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease, as well as to the medical professionals involved in treatment.

End

Contacts for Inquiries about this PR	
ZERIA Pharmaceutical Co., Ltd. Public Relations Tel: 03-3661-1039	Nichi-Iko Pharmaceutical Co., Ltd. President Office Tel: 076-442-7026